January 21, 2009 - TomoTherapy Inc. and Hitachi Medical Corporation (HMC) have entered into an exclusive agreement with to distribute the Hi-Art cancer treatment system in Japan, through the agreement, HMC will market, sell and service the innovative Hi-Art system, which facilitates highly precise, CT-guided radiation therapy for a wide range of clinical indications.
“Hitachi Medical Corporation is an ideal partner for us and for our valued customers, in one of our most important markets,” said TomoTherapy CEO Fred Robertson, M.D. “HMC’s robust national infrastructure and reputation for excellent technical and customer support will enhance our ability to service all hospitals in Japan that are currently using TomoTherapy technology. Additionally, this agreement represents a significant opportunity for us to reach new customers, and help advance the quality of cancer care across Japan, the second largest radiation therapy marketplace in the world.”
“The TomoTherapy Hi-Art system is being recognized as a novel radiation therapy system among Japanese customers. We believe that we can contribute to quality improvement of radiation therapy for cancer treatment in Japan through distribution and technical service of this system. And, we are going to strengthen our presence in the market by adding this system in our product portfolio as we become able to provide not only diagnostic solutions but also a treatment solution for customers in Japan,” said Hitachi Medical Vice President Michito Kinoshita.
For more information: www.tomotherapy.com
April 25, 2024 
